JPWO2023102448A5 - - Google Patents

Info

Publication number
JPWO2023102448A5
JPWO2023102448A5 JP2024532444A JP2024532444A JPWO2023102448A5 JP WO2023102448 A5 JPWO2023102448 A5 JP WO2023102448A5 JP 2024532444 A JP2024532444 A JP 2024532444A JP 2024532444 A JP2024532444 A JP 2024532444A JP WO2023102448 A5 JPWO2023102448 A5 JP WO2023102448A5
Authority
JP
Japan
Prior art keywords
deletion
amino acid
cov
glycoprotein
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024545420A5 (https=
JP2024545420A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080700 external-priority patent/WO2023102448A2/en
Publication of JP2024545420A publication Critical patent/JP2024545420A/ja
Publication of JP2024545420A5 publication Critical patent/JP2024545420A5/ja
Publication of JPWO2023102448A5 publication Critical patent/JPWO2023102448A5/ja
Pending legal-status Critical Current

Links

JP2024532444A 2021-11-30 2022-11-30 コロナウイルスワクチン製剤 Pending JP2024545420A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163284497P 2021-11-30 2021-11-30
US63/284,497 2021-11-30
US202163292120P 2021-12-21 2021-12-21
US63/292,120 2021-12-21
US202163293519P 2021-12-23 2021-12-23
US63/293,519 2021-12-23
US202263332530P 2022-04-19 2022-04-19
US63/332,530 2022-04-19
US202263367678P 2022-07-05 2022-07-05
US63/367,678 2022-07-05
PCT/US2022/080700 WO2023102448A2 (en) 2021-11-30 2022-11-30 Coronavirus vaccine formulations

Publications (3)

Publication Number Publication Date
JP2024545420A JP2024545420A (ja) 2024-12-06
JP2024545420A5 JP2024545420A5 (https=) 2025-11-13
JPWO2023102448A5 true JPWO2023102448A5 (https=) 2025-11-13

Family

ID=86613115

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532444A Pending JP2024545420A (ja) 2021-11-30 2022-11-30 コロナウイルスワクチン製剤

Country Status (10)

Country Link
US (1) US20250025549A1 (https=)
EP (1) EP4440613A4 (https=)
JP (1) JP2024545420A (https=)
KR (1) KR20240125935A (https=)
AU (1) AU2022399829A1 (https=)
CA (1) CA3241118A1 (https=)
IL (1) IL313254A (https=)
MX (1) MX2024006589A (https=)
TW (1) TW202332685A (https=)
WO (1) WO2023102448A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2024089638A1 (en) * 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine
US20250144200A1 (en) 2023-11-06 2025-05-08 Novavax, Inc. Intranasal immunogenic compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3165371A1 (en) * 2020-01-27 2021-08-05 Gale Smith Coronavirus vaccine formulations
JP2023511633A (ja) * 2020-01-28 2023-03-20 モデルナティエックス インコーポレイテッド コロナウイルスrnaワクチン
TW202204380A (zh) * 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗
KR20240123835A (ko) * 2021-12-23 2024-08-14 노바백스, 인코포레이티드 항-SARS-CoV-2 스파이크(S) 항체 및 COVID-19 치료에서의 그의 용도
CN119836572A (zh) * 2022-07-26 2025-04-15 诺瓦瓦克斯股份有限公司 用于评价疫苗免疫原性的ace2抑制测定
JP2025524959A (ja) * 2022-07-26 2025-08-01 ノババックス,インコーポレイテッド ワクチン免疫原性を評価するためのシュードウイルスベースの中和アッセイ

Similar Documents

Publication Publication Date Title
JP2026026092A5 (https=)
GB2610070A (en) Coronavirus vaccine formulations
US9951113B2 (en) Lectin compositions and methods for modulating an immune response to an antigen
US7504107B2 (en) Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response
US7629440B2 (en) Lectin compositions and methods for modulating an immune response to an antigen
EP1573047B1 (en) Lectin compositions and methods for modulating an immune response to an antigen
JP2005508916A5 (https=)
US20240390473A1 (en) Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
CN116655748B (zh) 一种截短型水痘-带状疱疹病毒gE蛋白及其应用
WO2019092002A1 (en) Pharmaceutical compositions for treatment or prevention of viral infections
US20210309973A1 (en) Bacteriophage-Based Antibodies and Binders
JPWO2023102448A5 (https=)
JPWO2021154812A5 (https=)
CN112439058A (zh) 基于外泌体为载体的重组新型冠状病毒纳米疫苗方法
EP0951554A1 (fr) Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
Wahren Gene vaccines
JPWO2022203963A5 (https=)
JPWO2022235663A5 (https=)
KR20120129893A (ko) 고령자에 보호 면역을 제공하기 위한 방법 및 조성물
JPWO2002062381A1 (ja) バキュロウイルスベクターワクチン
RU2023126867A (ru) Вакцинные составы против коронавируса
JPWO2021247789A5 (https=)
HK40088677A (en) Coronavirus vaccine formulations
AU2024225919A1 (en) Multicistronic vaccine and methods for producing and using the same
JPWO2023102375A5 (https=)